SCHEMBL3300046

SCHEMBL3300046

C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.80
KMT2A Q03164 6/20 0.80
ESR1 P03372 6/20 0.80
SMN1; SMN2 Q16637 5/20 0.80
ADORA3 P0DMS8 5/20 0.80
ATM Q13315 3/20 0.80
NR3C1 P04150 1/20 0.80
SHBG P04278 1/20 0.80
FYN P06241 1/20 0.80
ADRA2C P18825 1/20 0.80
SLC6A2 P23975 1/20 0.80
SLC6A4 P31645 1/20 0.80
HTR2B P41595 1/20 0.80
HTT P42858 1/20 0.80
MAPT P10636 6/20 0.72
CYP3A4 P08684 5/20 0.72
TP53 P04637 3/20 0.72
MEN1 O00255 4/20 0.68
THRB P10828 1/20 0.68
STS P08842 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299315 0.95 MAPT (0.81) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL8155723 0.95 MAPT (0.81) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL8722555 0.93 KMT2A (0.69) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL3864661 0.92 KMT2A (0.68) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL3870740 0.92 KMT2A (0.68) LMNAKMT2AESR1SMN1; SMN2ADORA3
Iodide SCHEMBL8723547 0.91 KMT2A (0.67) LMNAKMT2AESR1SMN1; SMN2ADORA3
Iodide SCHEMBL8723544 0.91 KMT2A (0.67) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL2596563 0.91 LMNA (0.71) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL19393251 0.90 KMT2A (0.70) LMNAKMT2AESR1SMN1; SMN2ADORA3
SCHEMBL8722468 0.90 MAPT (0.65) LMNAKMT2AESR1SMN1; SMN2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2073856-B1 COATED IMPLANT ARTIC GMBH (DE) 2014-03-05 EP disclosed
US-20100158974-A1 COATED IMPLANT SCHOEMIG ALBERT 2010-06-24 US disclosed
US-20100094410-A1 COATED IMPLANT SCHOEMIG ALBERT 2010-04-15 US disclosed
US-20090177280-A1 Implant With Multiple Coating SCHOEMIG ALBERT 2009-07-09 US disclosed
EP-1933893-A1 IMPLANT WITH MULTIPLE COATING Schömig, Albert (DE) 2008-06-25 EP disclosed
EP-1916006-A1 Implant coated with a wax or a resin Schömig, Albert (DE) 2008-04-30 EP disclosed
EP-1913960-A1 Coated implant Schömig, Albert (DE) 2008-04-23 EP disclosed
EP-1776970-A1 Implant with multiple coating Schömig, Albert (DE) 2007-04-25 EP disclosed
WO-2007042294-A1 IMPLANT WITH MULTIPLE COATING SCHOEMIG ALBERT (DE) 2007-04-19 WO disclosed
US-4009266-A METHOD OF TREATMENT OF NEMATODE PARASITE INFECTIONS IN DOMESTIC ANIMALS AYALEW LIYEW 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158974-A1 COATED IMPLANT CROCC, TET3, STUB1 LMNA 3724/4885KMT2A 266/4885ESR1 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.